Our team is at the forefront of utilizing prostate-specific membrane antigen (PSMA)-targeted therapies in the treatment of prostate cancer.
PSMA is a protein on the surface of prostate cancer cells that enables a targeted approach to locate and image or treat these cells wherever they are in the body, even those that have escaped (metastasized) to other organs. We are able to target PSMA using different types of drugs, including small molecules and antibodies.
Learn more about how we use antibodies and small molecules to target PSMA.
For examples of our work in action, browse open prostate cancer clinical trials at Weill Cornell Medicine and NewYork-Presbyterian.